IL1A and cancer: Nevertheless, PLGA IL‐1α‐MP administration (equivalent to 0.2 μg/mouse) to NFS/N mice bearing malignant fibrosarcoma tumors showed significantly longer survival rates compared to experimental controls although no toxicity end points were analyzed in vivo.48